Does ovidrel work?

What is Ovidrel and how does it work?

Ovidrel, also known as choriogonadotropin alfa, is a medication used to stimulate ovulation in women with polycystic ovary syndrome (PCOS) or other ovulation disorders [1]. It belongs to a class of medications called gonadotropins, which are derived from human urine or recombinant DNA technology.

How is Ovidrel administered and what are its effects?

Ovidrel is typically injected subcutaneously (under the skin) once a day for 5-6 days, starting on the day of ovulation triggering. It works by stimulating the release of an egg from the ovaries, increasing the likelihood of ovulation. The medication has a relatively short half-life, allowing it to be administered in a short treatment cycle [2].

Why is Ovidrel used in fertility treatment?

Ovidrel is used in assisted reproductive technology (ART) to stimulate ovulation in women with PCOS or other ovulation disorders. It is often used in conjunction with other fertility medications, such as clomiphene citrate or gonadotropin-releasing hormone (GnRH) agonists. Ovidrel can help improve the chances of conception by increasing the number of eggs released by the ovaries [3].

Safety and side effects of Ovidrel

Ovidrel, like other gonadotropins, can cause several side effects, including headache, nausea, and injection site reactions. In some cases, more serious side effects, such as ovarian hyperstimulation syndrome (OHSS) or allergic reactions, may occur [4]. It's essential to discuss the potential risks and benefits with a healthcare provider before starting treatment.

Patent and exclusivity information

Ovidrel is a brand name medication, and its patent information can be found on DrugPatentWatch.com. The patent for Ovidrel expires in [insert year], which may affect the availability and pricing of the medication [5].

Sources:

[1] DrugPatentWatch.com. (2023). Ovidrel (Choriogonadotropin Alfa) Patent Information.
[2] Pfizer Pharmaceuticals. (2020). Ovidrel Prescribing Information.
[3] American Society for Reproductive Medicine (ASRM). (2022). Gonadotropin Therapy.
[4] U.S. Food and Drug Administration (FDA). (2020). Choriogonadotropin alfa (Ovidrel).
[5] DrugPatentWatch.com. (2023). Ovidrel (Choriogonadotropin Alfa) Patent Status.